Prospective study of biomarkers and pharmacological characteristics for patients with metastatic lung tumors

Not Applicable

Recruiting

• Conditions: metastatic lung tumor

• Registration Number: JPRN-UMIN000053045
• Lead Sponsor: Keio University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-12-09
• Last Update Posted: 1 April 2024
• Study Completion: 2030-12-31

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 550

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who are deemed by the principal investigator or subinvestigator to be inappropriate to conduct this study.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Organoid establishment efficiency by primary tumor 1) Organoid establishment rate: Percentage of patients with metastatic lung tumor organoids cultured for a minimum of 6 spitzes per primary tumor, using metastatic lung tumor organoid cultures as the denominator. 2) Organoid establishment period: The period from the start date of metastatic lung tumor organoid culture to the date when at least 6 spits of organoids were frozen and cultured for each primary tumor. Drug sensitivity of organoids per primary tumor Drug efficacy evaluation of cytotoxic anticancer drugs such as platinum (cisplatin), antimetabolites (fluorouracil), and microvascular inhibitors (docetaxel, paclitaxel), and functional analysis of therapeutic target molecules will be performed in vitro or in vivo.